| Literature DB >> 35641535 |
Jina Yeo1,2, Eun-Ah Park3, Eun Bong Lee2, Jin Kyun Park4.
Abstract
To describe the peripheral angiographic features of vasculopathy in idiopathic inflammatory myopathies (IIM) and systemic sclerosis (SSc) in comparison to polyarteritis nodosa (PAN). Angiograms of 47 extremities (24 upper and 23 lower) of 11 patients with IIM (n = 5) and SSc (n = 6), and 12 patients with PAN who presented with critical limb ischemia were retrospectively analyzed with regards to the presence of stenosis, occlusion, aneurysms and delayed distal flow, and degree of neovascularization. Diffuse narrowing was more frequent (66.1 vs. 38.0%, p = 0.001), whereas multifocal stenosis (6.5% vs. 26.8%, p = 0.002), abrupt occlusion (11.3% vs. 29.6%, p = 0.010) and aneurysm formation (1.6% vs. 11.3%, p = 0.037) were less frequent in IIM/SSc than PAN. In distal arteries, tapered occlusion (95.5% vs. 76.0%, p = ns) and delayed flow (77.3% vs. 48.0%, p = 0.039) were more common in IIM/SSc than PAN. After 1 year, auto- or surgical amputation tended to be more frequent in IIM/SSc than PAN (36.4% vs. 16.7%, p = ns). In conclusion, diffuse narrowing, tapered occlusion and delayed distal flow on conventional angiograms tend to be more frequent in IIM/SSc than PAN. Further studies are needed to verify these findings in a larger prospective cohort.Entities:
Mesh:
Year: 2022 PMID: 35641535 PMCID: PMC9156678 DOI: 10.1038/s41598-022-12991-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Figure 1Angiographic features of IIM/SSc-vasculopathy and PAN. Arteries in the (A) upper extremities and (B) lower extremities of patients with IIM/SSc-vasculopathy and PAN. Diffuse narrowing is indicated by white arrowheads; tapered occlusion by white arrows; multifocal stenosis by black arrowheads; abrupt occlusion by black arrows; aneurysmal changes by empty arrows; grade 2 tortuosity by white stars; and grade 3 tortuosity by black stars. IIM idiopathic inflammatory myopathies, PAN polyarteritis nodosa, SSc systemic sclerosis.
Baseline demographic and laboratory characteristics of patients.
| Characteristics | IIM/SSc (n = 11) | PAN (n = 12) | |
|---|---|---|---|
| Age, years | 58.0 ± 13.0 | 52.4 ± 17.8 | 0.404 |
| Women, n (%) | 10 (90.9) | 6 (50.0) | 0.069 |
| Disease duration, years | 5.7 (2.0–10.0) | 3.7 (0.8–10.0) | 0.487 |
| Smoking history, n (%) | 0 (0.0) | 3 (25.0) | 0.217 |
| Body mass index, kg/m2 | 20.6 ± 2.9 | 24.0 ± 2.9 | |
| Systolic blood pressure, mmHg | 132.7 ± 18.4 | 135.2 ± 23.5 | 0.786 |
| Diastolic blood pressure, mmHg | 86.4 ± 11.2 | 83.4 ± 17.9 | 0.644 |
| Symptom duration of digital ischemia, years | 5.7 (1.0–9.4) | 0.4 (0.1–1.7) | |
| RP with digital pain or numbness | 2 (18.2) | 6 (50.0) | 0.193 |
| Digital cyanosis | 3 (27.3) | 4 (33.3) | 1.000 |
| Digital ulcer | 1 (9.1) | 2 (16.7) | 1.000 |
| Digital gangrene | 5 (45.5) | 0 (0.0) | |
| Hypertension | 4 (36.4) | 4 (33.3) | 1.000 |
| Diabetes mellitus | 1 (9.1) | 2 (16.7) | 1.000 |
| Dyslipidemia | 1 (9.1) | 3 (25.0) | 0.217 |
| Hepatitis B/C | 0 (0.0) | 3 (25.0) | 0.590 |
| Interstitial lung disease | 4 (36.4) | 0 (0.0) | |
| Pulmonary hypertension | 4 (36.4) | 0 (0.0) | |
| Malignancya | 1 (9.1) | 2 (16.7) | 1.000 |
| ESR mm/hr | 39.3 ± 20.7 | 41.8 ± 38.2 | 0.850 |
| CRP, mg/dL | 0.46 (0.12–1.04) | 0.87 (0.14–2.65) | 0.347 |
| Glucose, mg/dL | 88.0 (83.0–96.0) | 110.0 (88.3–137.3) | |
| Total cholesterol, mg/dL | 171.0 (151.0–257.0) | 149.0 (119.0–177.0) | 0.171 |
| Triglyceride, mg/dL, (n = 7/7) | 129.1 ± 76.8 | 110.7 ± 76.7 | 0.661 |
| LDL cholesterol, mg/dL (n = 7/8) | 117.4 ± 39.3 | 105.8 ± 39.8 | 0.580 |
| HDL cholesterol, mg/dL (n = 7/7) | 56.0 ± 23.5 | 55.0 ± 25.8 | 0.941 |
| D-dimer, ug/mL, (n = 6/11) | 1.2 (0.9–2.2) | 0.5 (0.3–0.9) | |
| Anti-nuclear antibody (≥ 1:80) | 7 (63.6) | 0 (0.0) | |
| Anti-neutrophil cytoplasmic antibody (≥ 1:40) | 0/8 (25.0) | 0/9 (0.0) | 0.206 |
| Anti-Jo-1 antibody | 1/4 (25.0) | – | – |
| Anti-centromere antibody | 5/10 (50.0) | 0/12 (0.0) | |
| Anti-Scl-70 antibody | 3/11 (27.3) | – | – |
| Anti-RNP antibody | 3/6 (50.0) | 0/2 (0.0) | 0.464 |
| Rheumatoid factor | 3/9 (33.3) | 0/12 (0.0) | 0.063 |
| Anti-cardiolipin antibody IgG/M | 0/6 (0.0) | 1/10 (1.0) | 1.000 |
| Anti-B2GPI antibody IgG/M | 0/6 (0.0) | 0/8 (0.0) | – |
| Lupus anticoagulant | 0/7 (0.0) | 3/11 (27.2) | 0.245 |
| Cryoglobulin | 1/6 (16.7) | 1/9 (11.1) | 1.000 |
| Azathioprine | 0 (0.0) | 7 (58.3) | |
| Cyclosporin | 5 (45.5) | 0 (0.0) | |
| Mycophenolate mofetil | 3 (27.3) | 1 (8.3) | 0.317 |
| Methotrexate | 1 (9.1) | 1 (8.3) | 1.000 |
| Tacrolimus | 1 (9.1) | 0 (0.0) | 0.478 |
| Cyclophosphamide | 1 (9.1) | 5 (41.7) | 0.155 |
| Rituximab | 1 (9.1) | 0 (0.0) | 0.478 |
| Glucocorticoid use, current, n (%) | 6 (54.5) | 9 (75.0) | 0.400 |
| Cum prednisone-equivalent dose, mgb | 478.8 (0.0–12,435.0) | 158.0 (6.3–828.1) | 0.566 |
| Cum prednisone-equivalent dose, mg/kgb | 9.0 (0.0–231.8) | 2.5 (0.1–13.1) | 0.347 |
| Average dose of prednisone-equivalent, mg/kg/dayb | 0.3 (0.0–0.3) | 0.2 (0.0–1.6) | 0.379 |
Data are expressed as mean ± SD or median (IQR) for continuous variables and number (%) of patients for categorical variables.
Significant values are in bold.
B2GPI beta2 glycoprotein I, CRP C-reactive protein, Cum cumulative, ESR erythrocyte sediment rate, HDL high-density lipoprotein, IIM idiopathic inflammatory myopathies, LDL low-density lipoprotein, PAN polyarteritis nodosa, RNP ribonucleoprotein, RP Raynaud’s phenomenon, SSc systemic sclerosis.
aOne colorectal cancer in IIM/SSc group and two hepatocellular carcinoma in PAN group.
bThe prednisone-equivalent dose includes oral and intravenous glucocorticoids.
Comparison of angiographic parameters between IIM/SSc-vasculopathy and PAN.
| IIM/SSc-vasculopathy (upper 14, lower 8) | PAN (upper 10, lower 15) | ||
|---|---|---|---|
| Total number of images | 62 | 71 | |
| Shoulder/elbow/wrist and hand | 11/14/14 | 8/10/10 | |
| Femoral/knee/ankle and foot | 7/8/8 | 13/15/15 | |
| Diffuse narrowing | 41/62 (66.1%) | 27/71 (38.0%) | |
| Focal stenosis | 13/62 (21.0%) | 10/71 (14.1%) | 0.295 |
| Multifocal stenosis | 4/62 (6.5%) | 19/71 (26.8%) | |
| Tapered occlusion | 27/62 (43.5%) | 23/71 (32.4%) | 0.185 |
| Abrupt occlusion | 7/62 (11.3%) | 21/71 (29.6%) | |
| Aneurysm | 1/62 (1.6%) | 8/71 (11.3%) | |
| Tortuositya | |||
| Grade 1 | 45/62 (72.6%) | 30/68 (39.1%) | |
| Grade 2 | 11/62 (17.7%) | 14/68 (23.9%) | |
| Grade 3 | 6/62 (9.7%) | 24/68 (37.0%) | |
IIM idiopathic inflammatory myopathies, PAN polyarteritis nodosa, SSc systemic sclerosis.
Significant values are in bold.
aTortuosity grade 1, normal; grade 2, mild to moderate; grade 3, severe (hypertortuosity). Data are expressed as number (%) of images.
Figure 2Angiographic parameters in the extremities of patients with IIM/SSc-vasculopathy and PAN. Angiographic features in arteries of the (A) proximal and (B) distal extremities of patients with IIM/SSc-vasculopathy and PAN. (C) Frequencies of neovascularization (hypertortuosity, grade 3) between the IIM/SSc-vasculopathy and PAN. IIM idiopathic inflammatory myopathies, PAN polyarteritis nodosa, SSc systemic sclerosis. Y-axis is the percentage (%) of total images.
Comparison of angiographic parameters in subgroups of IIM/SSc-vasculopathy.
| IIM-vasculopathy (upper 8, lower 3) | SSc-vasculopathy (upper 6, lower 5) | ||
|---|---|---|---|
| Total number of images | 31 | 31 | |
| Shoulder/elbow/wrist and hand | 6/8/8 | 5/6/6 | |
| Femoral/knee/ankle and foot | 3/3/3 | 4/5/5 | |
| Diffuse narrowing | 21/31 (67.7%) | 20/31 (64.5%) | 0.788 |
| Focal stenosis | 6/31 (19.4%) | 7/31 (22.6%) | 0.755 |
| Multifocal stenosis | 2/31 (6.5%) | 2/31 (6.5%) | 1.000 |
| Tapered occlusion | 13/31 (41.9%) | 14/31 (45.2%) | 0.798 |
| Abrupt occlusion | 5/31 (16.1%) | 2/31 (6.5%) | 0.425 |
| Aneurysm | 0/31 (0.0%) | 1/31 (3.2%) | 1.000 |
| Tortuositya | 0.407 | ||
| Grade 1 | 20/31 (64.5%) | 25/31 (80.6%) | |
| Grade 2 | 7/31 (22.6%) | 4/31 (12.9%) | |
| Grade 3 | 4/31 (12.9%) | 2/31 (6.5%) | |
Data are expressed as number (%) of images.
IIM idiopathic inflammatory myopathies, SSc systemic sclerosis.
aTortuosity grade 1, normal; grade 2, mild to moderate; grade 3, severe (hypertortuosity).
Treatment and 1-year outcome of limb ischemia.
| IIM/SSc-vasculopathy (n = 11) | PAN (n = 12) | ||
|---|---|---|---|
| Calcium channel blocker | 8 (72.7) | 3 (25.0) | |
| PDE5 inhibitor | 5 (45.5) | 0 (0.0) | |
| Prostanoid | 9 (81.8) | 5 (41.7) | 0.089 |
| Endothelin receptor antagonist | 3 (27.3) | 0 (0.0) | 0.093 |
| Aspirin | 5 (45.5) | 5 (41.7) | 1.000 |
| Clopidogrel | 1 (9.1) | 1 (8.3) | 1.000 |
| Cilostazol | 4 (36.4) | 5 (41.7) | 1.000 |
| Warfarin | 1 (9.1) | 1 (8.3) | 1.000 |
| Direct oral anticoagulant | 1 (9.1) | 0 (0.0) | 0.478 |
| Skin graft | 1 (9.1) | 0 (0.0) | 0.478 |
| Amputation | 2 (18.2) | 1 (8.3) | 0.590 |
| Bypass surgery | 0 (0.0) | 1 (8.3) | 1.000 |
| PTA, n (%) | 1. (9.1) | 1 (8.3) | 1.000 |
| Improved | 3 (27.3) | 7 (58.3) | 0.214 |
| Stationary | 4 (36.4) | 3 (25.0) | 0.667 |
| Amputation (auto- or surgical) | 4 (36.4) | 2 (16.7) | 0.371 |
Data are expressed as number (%) of patients.
Significant values are in bold.
IIM idiopathic inflammatory myopathies, PAN polyarteritis nodosa, PDE phosphodiesterase, PTA percutaneous transluminal angioplasty, SSc systemic sclerosis.